Evaxion Biotech announces new data to be presented at AACR meeting

Evaxion A/S announces new data demonstrating the platform’s ability to also potentially develop vaccines for glioblastoma. The data, which will be presented at the AACR Annual Meeting in San Diego, California, on April 22, is “another confirmation of how AI-Immunology can be applied across a range of different cancers as well as other diseases,” the company stated. “We are excited by these new findings confirming that AI-Immunology is a unique platform for designing vaccines for many different cancer types, combining neoantigens with other types of antigens. This holds great potential for improving vaccine efficacy, and we are looking forward to discussing the data with both scientific stakeholders and potential business partners at the AACR Annual Meeting,” says Birgitte Rono, CSO of Evaxion.